4.41
-0.33 (-6.87%)
| Penutupan Terdahulu | 4.73 |
| Jumlah Dagangan | 111,409 |
| Harga / Pendapatan (P/E Ke hadapan) | 18.62 |
| Harga / Jualan (P/S) | 1.82 |
| Harga / Buku (P/B) | 4.01 |
| Julat 52 Minggu |
| Margin Keuntungan | -14.76% |
| Margin Operasi (TTM) | -25.30% |
| EPS Cair (TTM) | -0.370 |
| Pertumbuhan Hasil Suku Tahunan (YOY) | 0.80% |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 116.83% |
| Nisbah Semasa (MRQ) | 1.34 |
| Aliran Tunai Operasi (OCF TTM) | -6.94 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -18.74 M |
| Pulangan Atas Aset (ROA TTM) | -5.70% |
| Pulangan Atas Ekuiti (ROE TTM) | -48.14% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Drug Manufacturers - Specialty & Generic (US) | Bercampur | Bercampur |
| Drug Manufacturers - Specialty & Generic (Global) | Bercampur | Bercampur | |
| Stok | Journey Medical Corporation | Bercampur | Bercampur |
AISkor Stockmoo
| Konsensus Penganalisis | 0.0 |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | 3.0 |
| Purata Bergerak Teknikal | 1.0 |
| Osilator Teknikal | -2.5 |
| Penilaian Relatif | NA |
| Kesihatan Kewangan | -3.0 |
| Persekitaran Makro | -1.3 |
| AI Insight | NA |
| AI Technical | NA |
| Purata | -0.24 |
|
Journey Medical Corp is a commercial-stage pharmaceutical company that focuses on the selling and marketing of U.S. Food and Drug Administration (FDA) approved prescription pharmaceutical products for the treatment of dermatological conditions. Its current product portfolio includes FDA-approved prescription drugs for dermatological conditions that are marketed in the U.S. The company views its operations and manages its business in one segment, which reflects products for the treatment of dermatological conditions. The dermatological segment derives revenues from the sale of branded and authorized general prescription products that treat certain dermatological conditions. |
|
| Sektor | Healthcare |
| Industri | Drug Manufacturers - Specialty & Generic |
| Gaya Pelaburan | Small Core |
| % Dimiliki oleh Orang Dalam | 30.89% |
| % Dimiliki oleh Institusi | 29.96% |
Tiada data dalam julat masa ini.
Tiada data dalam julat masa ini.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2026 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |